The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
reduction of scar tissue as a result of abdominal or pelvic surgery
Seprafilm bioresorbable membrane has been approved for use in
any open abdominal or pelvic surgery. Seprafilm is indicated for
use in subjects undergoing abdominal or pelvic open surgery as an
adjunct intended to reduce the incidence, extent, and severity of
postoperative adhesions (scar tissues) between the abdominal wall
and the underlying viscera such as omentum, small bowel, bladder,
and stomach, and between the uterus and surrounding structures such
as tubes and ovaries, large bowel, and bladder.
The effect of Seprafilm on long-term postoperative complications
(i.e. intestinal obstruction, female infertility, chronic pain) has
not yet been studied, but two clinical trials have shown that
Seprafilm reduced adhesion formation where the membrane was